Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 64.04 CNY -4.28% Market Closed
Market Cap: 17B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Suzhou Zelgen Biopharmaceuticals Co Ltd

Revenue
407.2m CNY
Cost of Revenue
-31.3m CNY
Gross Profit
375.9m CNY
Operating Expenses
-673.8m CNY
Operating Income
-297.9m CNY
Other Expenses
67m CNY
Net Income
-230.9m CNY

Income Statement
Suzhou Zelgen Biopharmaceuticals Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024
Revenue
Revenue
0
N/A
0
N/A
0
N/A
0
N/A
28
N/A
28
-1%
28
N/A
70
+153%
98
+40%
190
+94%
234
+23%
253
+8%
290
+14%
302
+4%
367
+21%
417
+14%
387
-7%
386
0%
387
+0%
407
+5%
Gross Profit
Cost of Revenue
(5)
(4)
(5)
(1)
(1)
(0)
(2)
(3)
(5)
(6)
(10)
(13)
(20)
(26)
(32)
(36)
(32)
(29)
(30)
(31)
Gross Profit
(5)
N/A
(4)
+16%
(5)
-23%
(1)
+90%
27
N/A
27
+1%
26
-5%
67
+157%
94
+40%
184
+97%
224
+22%
240
+7%
269
+12%
276
+3%
335
+21%
381
+14%
354
-7%
357
+1%
357
0%
376
+5%
Operating Income
Operating Expenses
(717)
(437)
(337)
(288)
(340)
(386)
(411)
(486)
(563)
(692)
(762)
(802)
(826)
(785)
(770)
(741)
(691)
(686)
(677)
(674)
Selling, General & Administrative
(564)
(266)
(145)
(70)
(76)
(93)
(98)
(127)
(177)
(212)
(256)
(280)
(296)
(300)
(336)
(310)
(291)
(253)
(266)
(292)
Research & Development
(152)
(151)
(206)
(235)
(291)
(269)
(338)
(382)
(429)
(469)
(547)
(567)
(565)
(458)
(468)
(463)
(440)
(459)
(489)
(457)
Depreciation & Amortization
(12)
(33)
0
0
0
(46)
0
0
0
(48)
0
0
0
(53)
0
0
0
(49)
0
0
Other Operating Expenses
11
14
14
17
28
22
24
23
44
37
41
45
34
26
34
32
40
74
78
76
Operating Income
(721)
N/A
(441)
+39%
(341)
+23%
(289)
+15%
(313)
-8%
(359)
-15%
(385)
-7%
(419)
-9%
(470)
-12%
(508)
-8%
(538)
-6%
(562)
-5%
(557)
+1%
(509)
+9%
(435)
+15%
(359)
+17%
(337)
+6%
(329)
+2%
(320)
+3%
(298)
+7%
Pre-Tax Income
Interest Income Expense
0
1
9
21
39
54
63
64
62
49
36
27
16
23
16
15
23
31
37
43
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
(0)
0
(0)
0
(0)
0
0
0
(0)
0
0
Total Other Income
0
0
0
0
0
0
0
(0)
(5)
(6)
(7)
(7)
(3)
(2)
(2)
(2)
(2)
(1)
(1)
(1)
Pre-Tax Income
(721)
N/A
(440)
+39%
(333)
+24%
(268)
+20%
(273)
-2%
(305)
-12%
(322)
-6%
(355)
-10%
(412)
-16%
(465)
-13%
(509)
-9%
(542)
-7%
(544)
0%
(488)
+10%
(421)
+14%
(346)
+18%
(315)
+9%
(299)
+5%
(284)
+5%
(256)
+10%
Net Income
Tax Provision
(12)
(8)
(8)
8
(7)
(6)
(6)
(6)
9
3
3
3
3
2
2
2
2
4
4
4
Income from Continuing Operations
(733)
(448)
(341)
(260)
(280)
(311)
(328)
(361)
(403)
(462)
(506)
(539)
(541)
(486)
(419)
(344)
(313)
(295)
(280)
(252)
Income to Minority Interest
(14)
(14)
(13)
11
(11)
(9)
(8)
(6)
20
11
15
18
19
28
24
19
17
17
19
21
Net Income (Common)
(747)
N/A
(462)
+38%
(354)
+23%
(249)
+30%
(292)
-17%
(319)
-9%
(337)
-5%
(368)
-9%
(384)
-4%
(451)
-18%
(491)
-9%
(521)
-6%
(522)
0%
(457)
+12%
(396)
+14%
(325)
+18%
(296)
+9%
(279)
+6%
(261)
+6%
(231)
+11%
EPS (Diluted)
-4.14
N/A
-2.57
+38%
-1.59
+38%
-1.08
+32%
-1.21
-12%
-1.36
-12%
-1.42
-4%
-1.54
-8%
-1.6
-4%
-1.88
-18%
-2.04
-9%
-2.17
-6%
-2.18
0%
-1.91
+12%
-1.65
+14%
-1.35
+18%
-1.06
+21%
-1.09
-3%
-1
+8%
-0.87
+13%

See Also

Discover More